Pliva

Infobox_Company
company_name = Pliva d.d.
company_
company_type = Public: ZSE: [http://www.zse.hr/security.php?ticker=PLVA-R-A PLVA-R-A] )
foundation = 1921
location = Zagreb, Croatia
key_people = Željko Čović, CEO
num_employees = Approximately 6,000 Q2 2006
industry = Pharmaceuticals
products = Generics
revenue = profit: $336 million (2005)
revenue: $1.174 billion (2005) | homepage = [http://www.pliva.com/ www.pliva.com]

Pliva d.d. is a Croatian pharmaceutical company, based in Zagreb, Croatia. One of the world's largest producers of generic adderall, it has seen drastic increases in revenue with an increasing number of patients being diagnosed with Attention Deficit Disorder (ADD). It is the largest pharmaceutical company in Southern Europe. [ [http://www.cfoeurope.com/displayStory.cfm/1736847 CFO Europe] ] Its current CEO is Željko Čović. Pliva has recently recast itself as a generic pharmaceutical company leaving its proprietary business behind.

Pliva operates in over 30 countries worldwide and is the leading pharmaceutical company based in Central and Eastern Europe. It specializes in the development, production and distribution of generic pharmaceutical products, including biologicals, cytostatics, and other generics, as well as active pharmaceutical ingredients.

Pliva has recently been hailed for its newer, stronger, and more effective forms of adderall. The FDA hesitated in granting approval until it had been thoroughly tested in a laboratory setting. Due to lax Croatian pharmaceutical laws, the generic form of adderall was slightly dilluted to be able to market and sell it in the United States of America.

A team of Pliva's researchers, Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski and Zrinka Tamburašev led by Dr. Slobodan Ðokić, discovered azithromycin in 1980. Azithromycin is marketed in Eastern Europe under the name Sumamed and was licensed to Pfizer who market it in Western Europe and the USA under the name Zithromax, where it is one of the top-selling antibiotics. Royalties from Pfizer provided PLIVA's main income stream until the expiry of the azithromycin patent in 2005. This income was used to fund expansion in Europe and the USA, although some acquisitions have been highly questionable, particularly the acquisition of Sanctura (trospium chloride tablets) in the USA, which failed dismally in the market and was ultimately sold again at a huge loss of about 150 million USD.

During the summer of 2006, Pliva was the subject of a bidding war between Iceland's Actavis and US-based Barr Pharmaceuticals marking the first significant takeover of a publicly traded Croatian corporation. Barr ultimately prevailed in the bidding when Actavis bowed out on September 18th, 2006. Barr's final bid of USD 141 per share valued Pliva at approximately 2.5 billion USD. Formal change of ownership took place on October 24th 2006.

References

External links

* [http://www.pliva.com/en Pliva Corporate Website]